Honeysuckle extracts as a potential inhibitor of SARS-CoV-2 infection
- PMID: 40385477
- PMCID: PMC12083240
- DOI: 10.3389/fphar.2025.1517585
Honeysuckle extracts as a potential inhibitor of SARS-CoV-2 infection
Abstract
Background: In the current era of coronavirus disease 2019 (COVID-19), we were interested in searching for medications other than the currently available antiviral drugs Paxlovid and Molnupiravir that cause minimal side effects and do not harm the human body. Honeysuckle extract (HSE) is a traditional Chinese medicine (TCM) that has been shown to exert antiviral effects in other studies. However, no studies have indicated whether HSE has an inhibitory effect on SARS-CoV-2.
Methods: We prepared HSEs from dried honeysuckle flowers. We performed a cell viability assay, median tissue culture infection dose (TCID50) assay, and qRT‒PCR, and calculated the virus titers using the Reed-Muench method to evaluate the inhibitory effects of aqueous and alcohol HSEs on SARS‒CoV‒2 and explore the possible underlying mechanisms.
Results: In this study, post-treatment with HSE resulted in dose-dependent decreases in both the RNA levels and TCID50 of SARS-CoV-2 in Vero E6 cells; treatment with 50 μg/ml and 100 μg/ml alcohol HSEs achieved up to 95.323% and 92.587% inhibition, respectively. Moreover, pre-treatment with aqueous HSEs effectively reduced the RNA levels, and TCID50 of SARS-CoV-2 by up to 99.684%, and alcohol HSEs achieved up to 99.921% inhibition; both of these effects occurred in a dose-dependent manner.
Conclusion: The results suggest that HSEs may have the potential to prevent SARS-CoV-2 infection.
Keywords: COVID-19; Lonicera japonica Thunb.; SARS-CoV-2; extracts; honeysuckle.
Copyright © 2025 Lin, Lee, Liu, Chiou, Chen, Tsai and Tsai.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Honeysuckle Aqueous Extracts Induced let-7a Suppress EV71 Replication and Pathogenesis In Vitro and In Vivo and Is Predicted to Inhibit SARS-CoV-2.Viruses. 2021 Feb 16;13(2):308. doi: 10.3390/v13020308. Viruses. 2021. PMID: 33669264 Free PMC article.
-
Honeysuckle (Lonicera japonica) and Huangqi (Astragalus membranaceus) Suppress SARS-CoV-2 Entry and COVID-19 Related Cytokine Storm in Vitro.Front Pharmacol. 2022 Mar 25;12:765553. doi: 10.3389/fphar.2021.765553. eCollection 2021. Front Pharmacol. 2022. PMID: 35401158 Free PMC article.
-
In vitro anti-severe acute respiratory syndrome coronavirus 2 effect of Ephedra przewalskii Stapf extract.J Ethnopharmacol. 2024 Jan 30;319(Pt 3):117341. doi: 10.1016/j.jep.2023.117341. Epub 2023 Oct 23. J Ethnopharmacol. 2024. PMID: 37879507
-
Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases.Phytomed Plus. 2023 Feb;3(1):100402. doi: 10.1016/j.phyplu.2022.100402. Epub 2022 Dec 30. Phytomed Plus. 2023. PMID: 36597465 Free PMC article. Review.
-
Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.J Ethnopharmacol. 2021 Apr 24;270:113869. doi: 10.1016/j.jep.2021.113869. Epub 2021 Jan 21. J Ethnopharmacol. 2021. PMID: 33485973 Free PMC article.
References
-
- Beeraka N. M., Tulimilli S. V., Karnik M., Sadhu S. P., Pragada R. R., Aliev G., et al. (2021). The current Status and Challenges in the development of Vaccines and drugs against severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). Biomed. Res. Int. 2021, 8160860. 10.1155/2021/8160860 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous